查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1349443

抗感染藥物市場（藥物類別：抗菌藥、抗病毒藥、抗真菌藥物等；給藥途徑：口服、腸胃外等）- 全球產業分析、規模、佔有率、成長、趨勢和預測，2023-2031 年

Anti-Infective Drugs Market (Drug Class: Antibacterials, Antivirals, Antifungals, and Others; and Route of Administration: Oral, Parenteral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 190 Pages | 商品交期: 2-10個工作天內

價格

抗感染藥物市場 - 報告範圍

TMR 關於全球抗感染藥物市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球抗感染藥物的收入2017-2031 年感染性藥品市場，以2023 年為基準年，2031 年為預測年。報告中也提供了2023年至2031年全球抗感染藥物市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解抗感染藥物市場。

市場概況
2023年市場價值 1,391 億美元
2031 年市場價值 1,779 億美元
年複合成長率 0.04%

該報告深入探討了全球抗感染藥物市場的競爭格局。全球抗感染藥物市場的主要參與者已被確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、近期發展和 SWOT 是本報告中介紹的全球抗感染藥物市場參與者的屬性。

目錄

第一章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 全球主要國家的疾病盛行率和發生率
  • 監管場景：按地區
  • 按地區/全球分類的報銷方案
  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對產業的影響（價值鍊和短期/中期/長期影響）

第 6 章：全球市場分析與預測：依藥物類別

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依藥品類別，2017-2031
    • 抗菌劑
      • B-內醯胺類
      • 奎諾酮類
      • 大環內酯類
      • 四環素
      • 氨基糖苷類
      • 其他
    • 抗病毒藥
      • 其他抗病毒藥物
      • 金剛烷抗病毒藥
      • 抗病毒增強劑
      • 其他
    • 抗黴菌藥
      • 唑類
      • 棘白菌素
      • 多烯
      • 其他
    • 其他
  • 市場吸引力分析：依藥品類別

第 7 章：全球市場分析與預測：按給藥途徑

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依給藥途徑，2017-2031
    • 口服
    • 注射用
    • 其他
  • 市場吸引力分析：按給藥途徑

第 8 章：全球市場分析與預測：依指標分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依指標分類，2017-2031
    • 肺炎
    • 敗血症
    • 結核
    • 流感
    • 愛滋病毒感染
    • 肝炎病毒感染
    • 呼吸道病毒感染
    • 其他
  • 市場吸引力分析：依指標分類

第 9 章：全球市場分析與預測：按分銷管道

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：2017-2031年按通路
    • 醫院藥房
    • 零售藥局
    • 網路藥局
  • 市場吸引力分析：按分銷管道

第 10 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 按國家/地區分類的市場吸引力

第 11 章：北美市場分析與預測

第 12 章：歐洲市場分析與預測

第 13 章：亞太市場分析與預測

第 14 章：拉丁美洲市場分析與預測

第 15 章：中東和非洲市場分析與預測

第16章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類，2022 年
  • 公司簡介
    • Pfizer Inc.
    • Gland Pharma Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • GlaxoSmithKline plc
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • Abbott
    • Astellas Pharma Inc.
    • Alkem Laboratories
    • AstraZeneca
    • Eli Lilly and Company
    • Johnson & Johnson Services, Inc.
    • Takeda Pharmaceutical Company Limited
    • Sanofi
Product Code: TMRGL41204

Anti-Infective Drugs Market - Scope of Report

TMR's report on the global anti-infective drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global anti-infective drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anti-infective drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anti-infective drugs market.

Market Snapshot
Market Value in 2023US$ 139.1 Bn
Market Value in 2031US$ 177.9 Bn
CAGR4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anti-infective drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global anti-infective drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anti-infective drugs market.

The report delves into the competitive landscape of the global anti-infective drugs market. Key players operating in the global anti-infective drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global anti-infective drugs market profiled in this report.

Key Questions Answered in Global Anti-Infective Drugs Market Report:

  • What is the sales/revenue generated by anti-infective drugs across all regions during the forecast period?
  • What are the opportunities in the global anti-infective drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Anti-Infective Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global anti-infective drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global anti-infective drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global anti-infective drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anti-infective Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Anti-infective Drugs Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.2. Regulatory Scenario, by Region
  • 5.3. Reimbursement Scenario by Region/Globally
  • 5.4. Pipeline Analysis
  • 5.5. Key Product/Brand Analysis
  • 5.6. Key Mergers & Acquisitions
  • 5.7. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)

6. Global Anti-infective Drugs Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Antibacterials
      • 6.3.1.1. B-lactams
      • 6.3.1.2. Quinolones
      • 6.3.1.3. Macrolides
      • 6.3.1.4. Tetracycline
      • 6.3.1.5. Aminoglycoside
      • 6.3.1.6. Others
    • 6.3.2. Antivirals
      • 6.3.2.1. Miscellaneous Antivirals
      • 6.3.2.2. Adamantane Antivirals
      • 6.3.2.3. Antiviral Boosters
      • 6.3.2.4. Others
    • 6.3.3. Antifungals
      • 6.3.3.1. Azoles
      • 6.3.3.2. Echinocandins
      • 6.3.3.3. Polyenes
      • 6.3.3.4. Others
    • 6.3.4. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Anti-infective Drugs Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Anti-infective Drugs Market Analysis and Forecast, by Indication

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Indication, 2017-2031
    • 8.3.1. Pneumonia
    • 8.3.2. Sepsis
    • 8.3.3. Tuberculosis
    • 8.3.4. Influenza
    • 8.3.5. HIV Infection
    • 8.3.6. Hepatitis Virus Infection
    • 8.3.7. Respiratory Virus Infection
    • 8.3.8. Others
  • 8.4. Market Attractiveness Analysis, by Indication

9. Global Anti-infective Drugs Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Anti-infective Drugs Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Country/Region

11. North America Anti-infective Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Antibacterials
      • 11.2.1.1. B-lactams
      • 11.2.1.2. Quinolones
      • 11.2.1.3. Macrolides
      • 11.2.1.4. Tetracycline
      • 11.2.1.5. Aminoglycoside
      • 11.2.1.6. Others
    • 11.2.2. Antivirals
      • 11.2.2.1. Miscellaneous Antivirals
      • 11.2.2.2. Adamantane Antivirals
      • 11.2.2.3. Antiviral Boosters
      • 11.2.2.4. Others
    • 11.2.3. Antifungals
      • 11.2.3.1. Azoles
      • 11.2.3.2. Echinocandins
      • 11.2.3.3. Polyenes
      • 11.2.3.4. Others
    • 11.2.4. Others
  • 11.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Oral
    • 11.3.2. Parenteral
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Indication, 2017-2031
    • 11.4.1. Pneumonia
    • 11.4.2. Sepsis
    • 11.4.3. Tuberculosis
    • 11.4.4. Influenza
    • 11.4.5. HIV Infection
    • 11.4.6. Hepatitis Virus Infection
    • 11.4.7. Respiratory Virus Infection
    • 11.4.8. Others
  • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Route of Administration
    • 11.7.3. By Indication
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country/Sub-region

12. Europe Anti-infective Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Antibacterials
      • 12.2.1.1. B-lactams
      • 12.2.1.2. Quinolones
      • 12.2.1.3. Macrolides
      • 12.2.1.4. Tetracycline
      • 12.2.1.5. Aminoglycoside
      • 12.2.1.6. Others
    • 12.2.2. Antivirals
      • 12.2.2.1. Miscellaneous Antivirals
      • 12.2.2.2. Adamantane Antivirals
      • 12.2.2.3. Antiviral Boosters
      • 12.2.2.4. Others
    • 12.2.3. Antifungals
      • 12.2.3.1. Azoles
      • 12.2.3.2. Echinocandins
      • 12.2.3.3. Polyenes
      • 12.2.3.4. Others
    • 12.2.4. Others
  • 12.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.3.1. Oral
    • 12.3.2. Parenteral
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Indication, 2017-2031
    • 12.4.1. Pneumonia
    • 12.4.2. Sepsis
    • 12.4.3. Tuberculosis
    • 12.4.4. Influenza
    • 12.4.5. HIV Infection
    • 12.4.6. Hepatitis Virus Infection
    • 12.4.7. Respiratory Virus Infection
    • 12.4.8. Others
  • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Route of Administration
    • 12.7.3. By Indication
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Anti-infective Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Antibacterials
      • 13.2.1.1. B-lactams
      • 13.2.1.2. Quinolones
      • 13.2.1.3. Macrolides
      • 13.2.1.4. Tetracycline
      • 13.2.1.5. Aminoglycoside
      • 13.2.1.6. Others
    • 13.2.2. Antivirals
      • 13.2.2.1. Miscellaneous Antivirals
      • 13.2.2.2. Adamantane Antivirals
      • 13.2.2.3. Antiviral Boosters
      • 13.2.2.4. Others
    • 13.2.3. Antifungals
      • 13.2.3.1. Azoles
      • 13.2.3.2. Echinocandins
      • 13.2.3.3. Polyenes
      • 13.2.3.4. Others
    • 13.2.4. Others
  • 13.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.3.1. Oral
    • 13.3.2. Parenteral
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Indication, 2017-2031
    • 13.4.1. Pneumonia
    • 13.4.2. Sepsis
    • 13.4.3. Tuberculosis
    • 13.4.4. Influenza
    • 13.4.5. HIV Infection
    • 13.4.6. Hepatitis Virus Infection
    • 13.4.7. Respiratory Virus Infection
    • 13.4.8. Others
  • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. India
    • 13.6.3. Japan
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Route of Administration
    • 13.7.3. By Indication
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Anti-infective Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Antibacterials
      • 14.2.1.1. B-lactams
      • 14.2.1.2. Quinolones
      • 14.2.1.3. Macrolides
      • 14.2.1.4. Tetracycline
      • 14.2.1.5. Aminoglycoside
      • 14.2.1.6. Others
    • 14.2.2. Antivirals
      • 14.2.2.1. Miscellaneous Antivirals
      • 14.2.2.2. Adamantane Antivirals
      • 14.2.2.3. Antiviral Boosters
      • 14.2.2.4. Others
    • 14.2.3. Antifungals
      • 14.2.3.1. Azoles
      • 14.2.3.2. Echinocandins
      • 14.2.3.3. Polyenes
      • 14.2.3.4. Others
    • 14.2.4. Others
  • 14.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.3.1. Oral
    • 14.3.2. Parenteral
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Indication, 2017-2031
    • 14.4.1. Pneumonia
    • 14.4.2. Sepsis
    • 14.4.3. Tuberculosis
    • 14.4.4. Influenza
    • 14.4.5. HIV Infection
    • 14.4.6. Hepatitis Virus Infection
    • 14.4.7. Respiratory Virus Infection
    • 14.4.8. Others
  • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Route of Administration
    • 14.7.3. By Indication
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Anti-infective Drugs Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2017-2031
    • 15.2.1. Antibacterials
      • 15.2.1.1. B-lactams
      • 15.2.1.2. Quinolones
      • 15.2.1.3. Macrolides
      • 15.2.1.4. Tetracycline
      • 15.2.1.5. Aminoglycoside
      • 15.2.1.6. Others
    • 15.2.2. Antivirals
      • 15.2.2.1. Miscellaneous Antivirals
      • 15.2.2.2. Adamantane Antivirals
      • 15.2.2.3. Antiviral Boosters
      • 15.2.2.4. Others
    • 15.2.3. Antifungals
      • 15.2.3.1. Azoles
      • 15.2.3.2. Echinocandins
      • 15.2.3.3. Polyenes
      • 15.2.3.4. Others
    • 15.2.4. Others
  • 15.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 15.3.1. Oral
    • 15.3.2. Parenteral
    • 15.3.3. Others
  • 15.4. Market Value Forecast, by Indication, 2017-2031
    • 15.4.1. Pneumonia
    • 15.4.2. Sepsis
    • 15.4.3. Tuberculosis
    • 15.4.4. Influenza
    • 15.4.5. HIV Infection
    • 15.4.6. Hepatitis Virus Infection
    • 15.4.7. Respiratory Virus Infection
    • 15.4.8. Others
  • 15.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Drug Class
    • 15.7.2. By Route of Administration
    • 15.7.3. By Indication
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company, 2022
  • 16.3. Company Profiles
    • 16.3.1. Pfizer Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Gland Pharma Ltd.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Teva Pharmaceutical Industries Ltd.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. F. Hoffmann-La Roche Ltd.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Novartis AG
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. GlaxoSmithKline plc
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Gilead Sciences, Inc.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Merck & Co., Inc.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Abbott
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Astellas Pharma Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Alkem Laboratories
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. AstraZeneca
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview
    • 16.3.13. Eli Lilly and Company
      • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.13.2. Product Portfolio
      • 16.3.13.3. Financial Overview
      • 16.3.13.4. SWOT Analysis
      • 16.3.13.5. Strategic Overview
    • 16.3.14. Johnson & Johnson Services, Inc.
      • 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.14.2. Product Portfolio
      • 16.3.14.3. Financial Overview
      • 16.3.14.4. SWOT Analysis
      • 16.3.14.5. Strategic Overview
    • 16.3.15. Takeda Pharmaceutical Company Limited
      • 16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.15.2. Product Portfolio
      • 16.3.15.3. Financial Overview
      • 16.3.15.4. SWOT Analysis
      • 16.3.15.5. Strategic Overview
    • 16.3.16. Sanofi
      • 16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.16.2. Product Portfolio
      • 16.3.16.3. Financial Overview
      • 16.3.16.4. SWOT Analysis
      • 16.3.16.5. Strategic Overview

List of Tables

  • Table 01: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 03: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 04: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 05: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 06: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 07: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 08: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 09: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 10: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 11: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 12: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 13: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 14: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 15: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 17: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 18: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 19: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 20: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 21: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 22: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 23: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 25: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 26: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 27: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 28: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 29: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 30: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 31: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 32: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 33: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 34: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 35: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 36: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 37: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 38: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 39: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 40: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 41: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 42: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 43: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 44: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 45: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 46: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 47: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 48: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 03: Global Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 04: Global Anti-infective Drugs Market Revenue (US$ Mn), by Antibacterials, 2017-2031
  • Figure 05: Global Anti-infective Drugs Market Revenue (US$ Mn), by Antivirals, 2017-2031
  • Figure 06: Global Anti-infective Drugs Market Revenue (US$ Mn), by Antifungals, 2017-2031
  • Figure 07: Global Anti-infective Drugs Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 08: Global Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 09: Global Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 10: Global Anti-infective Drugs Market Revenue (US$ Mn), by Oral, 2017-2031
  • Figure 11: Global Anti-infective Drugs Market Revenue (US$ Mn), by Parenteral, 2017-2031
  • Figure 12: Global Anti-infective Drugs Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 13: Global Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 14: Global Anti-infective Drugs Market Revenue (US$ Mn), by Pneumonia, 2017-2031
  • Figure 15: Global Anti-infective Drugs Market Revenue (US$ Mn), by Sepsis, 2017-2031
  • Figure 16: Global Anti-infective Drugs Market Revenue (US$ Mn), by Tuberculosis, 2017-2031
  • Figure 17: Global Anti-infective Drugs Market Revenue (US$ Mn), by Influenza, 2017-2031
  • Figure 18: Global Anti-infective Drugs Market Revenue (US$ Mn), by HIV Infection, 2017-2031
  • Figure 19: Global Anti-infective Drugs Market Revenue (US$ Mn), by Hepatitis Virus Infection, 2017-2031
  • Figure 20: Global Anti-infective Drugs Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 21: Global Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 22: Global Anti-infective Drugs Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 23: Global Anti-infective Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 24: Global Anti-infective Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 25: Global Anti-infective Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 26: Global Anti-infective Drugs Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 27: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: North America Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 29: North America Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 30: North America Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 31: North America Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 32: North America Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 33: North America Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 34: North America Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 35: North America Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 36: North America Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 37: North America Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 38: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 39: Europe Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 40: Europe Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 41: Europe Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 42: Europe Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 43: Europe Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 44: Europe Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 45: Europe Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 46: Europe Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 47: Europe Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 48: Europe Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 49: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 51: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 52: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 53: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 54: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 55: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 56: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 57: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 58: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 59: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 60: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Latin America Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 62: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 63: Latin America Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 64: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 65: Latin America Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 66: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 67: Latin America Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 68: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 69: Latin America Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 70: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 71: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 72: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 73: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 74: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 75: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 76: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 77: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 78: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 79: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 80: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 81: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 82: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031